Shannon Heaning, Content Associate

San Diego meeting highlights inflammatory dermatoses, skin cancer, alopecia, and emerging therapeutic advances

July's FDA news was quiet, but an infant AD filing, JAK-refractory alopecia data, and a new device clearance hint at what's next.

Catch Up on Coverage From Day 1 of the 3rd Annual Elevate-Derm Summer Conference

Systematic review highlights AI-supported triage, nursing education, and workforce strategies for underserved communities

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Survey highlights APP autonomy, prescribing confidence, and treatment priorities in atopic dermatitis care

Long-term TNF inhibitor use was associated with significantly increased risks of melanoma and nonmelanoma skin cancer in a large cohort study.

Stay ahead with a weekly roundup of the biggest practice management, AI, policy, business, and professional development updates in dermatology.

NPF guidance outlines patient selection, counseling, and multidisciplinary management of GLP-1 receptor agonists in psoriasis.

IEC modified Delphi process establishes standardized treatment targets for atopic dermatitis

A new commentary argues primary or acute care experience should be a prerequisite for clinicians entering aesthetic medicine to improve patient safety and clinical decision-making.

A JAMA Dermatology study found expert dermatologists achieved the highest multiclass diagnostic accuracy when tested against AI across a realistic spectrum of skin lesions.

Christopher Bunick, MD, PhD, discussed new data suggesting emergency departments continue to rely on outdated therapies for pediatric atopic dermatitis flares despite evolving dermatology guidelines.

Konika Patel Schallen, MD, discussed how nanofractional laser treatments may support regenerative skin health beyond cosmetic improvement and outlined the next research priorities in a recent Dermatology Times interview

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Eugene R. Semenov, MD, MA, FAAD, discussed AI models that combine pathology and clinical data to better predict recurrence in early-stage melanoma

New York has extended independent practice authority for qualified nurse practitioners through July 1, 2030, preserving the current framework and collaboration requirements.

Konika Patel Schallen, MD, senior vice president and medical director of global clinical operations at Candela Medical, discussed epigenetic changes linked to laser skin resurfacing in a recent Dermatology Times interview.

Christopher Bunick, MD, PhD, discussed the scientific advances still needed before precision medicine can guide individualized therapy selection in atopic dermatitis during a recent Dermatology Times interview.

Extended-release oral minoxidil candidate VDPHL01 improved hair counts and patient-reported outcomes in women with pattern hair loss in a phase 2 study.

Peter Lio, MD, discussed how stress, sleep disruption, and patient-centered communication can influence pediatric atopic dermatitis management during a recent Skin and Psych podcast interview.

New JCI research identifies succinate/SUCNR1 signaling as a potential mechanistic link between hyperglycemia and worsening vitiligo.

The FDA accepted an sNDA for roflumilast cream 0.05% in infants, potentially expanding steroid-free treatment options for atopic dermatitis.

Konika Patel Schallen, MD, discussed new findings showing the Nordlys 1940 nm non-ablative fractional laser may reverse epigenetic markers of skin aging in a recent Dermatology Times interview.

Roman Bronfenbrener, MD, discussed changing exit strategies, private equity, and why peer support may be one of the most valuable resources for independent dermatologists.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed GX-03's encouraging interim safety profile, regulatory strategy, and next steps in clinical development.

A new real-world study found CSU was linked to stress-related disorders, but not a broad increase in new-onset psychiatric disease.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Christopher Bunick, MD, PhD, shared practical guidance on sun protection, swimming, and preserving the skin barrier in patients with atopic dermatitis.

Lynk Pharmaceuticals has dosed the first patient in a phase 2 trial evaluating investigational topical pan-JAK inhibitor LNK01004 for vitiligo.